| Dr Amanda Marie Beccaloni, DNP, CRNA, FNP-BC | |
|
3225 Spartan Rd, Olney, MD 20832-2335 | |
| (570) 650-0191 | |
| Not Available |
| Full Name | Dr Amanda Marie Beccaloni |
|---|---|
| Gender | Female |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 3225 Spartan Rd, Olney, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093032492 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 193062 (Maryland) | Primary |
| 363LF0000X | Nurse Practitioner - Family | 9264304 (Florida) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amanda Marie Beccaloni, DNP, CRNA, FNP-BC 23 Pierside Dr, Apt. 429, Baltimore, MD 21230-5463 Ph: (570) 650-0191 | Dr Amanda Marie Beccaloni, DNP, CRNA, FNP-BC 3225 Spartan Rd, Olney, MD 20832-2335 Ph: (570) 650-0191 |
News Archive
Winola Lake has partnered with STAT Ticket, a Boston, Massachusetts based software company, to provide a unique hospital issue reporting system.
Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.
Three researchers from the Virginia Bioinformatics Institute (VBI) at Virginia Tech have developed and evaluated a new one-step bioanalytical approach that allows them to profile in detail complex cellular extracts of proteins. The method has allowed the scientists to look at how the levels of proteins change in breast cancer cells when they are treated with hormones or cancer drugs like tamoxifen.
Researchers in the Duke Institute for Genome Sciences & Policy have developed a model for predicting risk of recurrence in early stage colon cancer patients, and have used the model to also predict sensitivity to chemotherapy and targeted therapy regimens.
Colorectal cancer is the second leading cause of cancer deaths, according to background information in the article. Screening asymptomatic patients is an important strategy for reducing these deaths, because by the time patients experience symptoms, the cancer may have progressed beyond the point where it can be cured.
› Verified 7 days ago
Barbara W. Dawson, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 18101 Prince Philip Dr, Olney, MD 20832 Phone: 301-774-8610 | |
Jennifer L Nevala, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 18101 Prince Philip Dr, Olney, MD 20832 Phone: 301-598-5100 | |
Lisandra Rojas, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 18101 Prince Philip Dr, Olney, MD 20832 Phone: 301-774-8610 | |
Mr. David J Weltz, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 18101 Prince Philip Dr, Olney, MD 20832 Phone: 301-774-8618 | |
Mrs. Elizabeth Delahay Wojno, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 18101 Prince Philip Dr, Olney, MD 20832 Phone: 301-774-8618 |